FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183863241> ?p ?o ?g. }

• W2183863241 endingPage "33" @default.
• W2183863241 startingPage "29" @default.
• W2183863241 abstract "Front line treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) and chemotherapy (CHT) results in molecular remission in approximately 95% of patients tested after consolidation. The small fraction of patients with persistence of molecular disease (i.e. those in whom polymerase chain reaction (PCR) is positive for PML/RARalpha) after such therapy are thought to have a dismal prognosis but has not yet been investigated in detail.We analyzed the clinico-biological features at presentation of APL patients who showed PCR-detectable residual disease and compared them to those of patients achieving molecular remission after AIDA induction and consolidation. Furthermore, we report the outcome of patients with molecularly persistent disease treated with salvage therapy.Patients attaining molecular remission (n=650) and patients who tested PCR+ve at the end of consolidation (n=23) were not statistically significantly different as regards median age, white cell and platelet counts, morphologic subtype (M3 or M3v), fibrinogen levels or PML/RARalpha transcript type. As to treatment outcome after salvage therapy, 7 patients were treated before morphologic relapse [3 with chemotherapy and autologous stem cell transplantation (SCT) and 4 with allogeneic SCT], and are alive after 64-118 months. Of 16 patients treated at the time of morphologic relapse, only 2 patients are alive, both of whom received an allogeneic SCT.Our findings indicate that APL patients who are molecularly resistant to the AIDA protocol have no distinguishing features at presentation. Their outcome suggests the need for early therapeutic intervention with aggressive treatment prior to the occurrence of hematologic relapse." @default.
• W2183863241 created "2016-06-24" @default.
• W2183863241 creator A5014873864 @default.
• W2183863241 creator A5016753594 @default.
• W2183863241 creator A5020457631 @default.
• W2183863241 creator A5022712318 @default.
• W2183863241 creator A5028913158 @default.
• W2183863241 creator A5049594325 @default.
• W2183863241 creator A5051410620 @default.
• W2183863241 creator A5058253118 @default.
• W2183863241 creator A5078192708 @default.
• W2183863241 creator A5087863588 @default.
• W2183863241 creator A5089760320 @default.
• W2183863241 date "2004-01-01" @default.
• W2183863241 modified "2023-09-28" @default.
• W2183863241 title "Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy." @default.
• W2183863241 cites W1521479021 @default.
• W2183863241 cites W1531493896 @default.
• W2183863241 cites W1576475831 @default.
• W2183863241 cites W1608690818 @default.
• W2183863241 cites W1894820534 @default.
• W2183863241 cites W1966906635 @default.
• W2183863241 cites W2024355870 @default.
• W2183863241 cites W2046657068 @default.
• W2183863241 cites W2050863148 @default.
• W2183863241 cites W2073409515 @default.
• W2183863241 cites W2077941517 @default.
• W2183863241 cites W2115874632 @default.
• W2183863241 cites W2134362985 @default.
• W2183863241 cites W2414522594 @default.
• W2183863241 cites W78907138 @default.
• W2183863241 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14754603" @default.
• W2183863241 hasPublicationYear "2004" @default.
• W2183863241 type Work @default.
• W2183863241 sameAs 2183863241 @default.
• W2183863241 citedByCount "16" @default.
• W2183863241 countsByYear W21838632412013 @default.
• W2183863241 countsByYear W21838632412014 @default.
• W2183863241 countsByYear W21838632412019 @default.
• W2183863241 countsByYear W21838632412021 @default.
• W2183863241 crossrefType "journal-article" @default.
• W2183863241 hasAuthorship W2183863241A5014873864 @default.
• W2183863241 hasAuthorship W2183863241A5016753594 @default.
• W2183863241 hasAuthorship W2183863241A5020457631 @default.
• W2183863241 hasAuthorship W2183863241A5022712318 @default.
• W2183863241 hasAuthorship W2183863241A5028913158 @default.
• W2183863241 hasAuthorship W2183863241A5049594325 @default.
• W2183863241 hasAuthorship W2183863241A5051410620 @default.
• W2183863241 hasAuthorship W2183863241A5058253118 @default.
• W2183863241 hasAuthorship W2183863241A5078192708 @default.
• W2183863241 hasAuthorship W2183863241A5087863588 @default.
• W2183863241 hasAuthorship W2183863241A5089760320 @default.
• W2183863241 hasConcept C126322002 @default.
• W2183863241 hasConcept C143998085 @default.
• W2183863241 hasConcept C203014093 @default.
• W2183863241 hasConcept C2776601000 @default.
• W2183863241 hasConcept C2776694085 @default.
• W2183863241 hasConcept C2778461978 @default.
• W2183863241 hasConcept C2779050716 @default.
• W2183863241 hasConcept C2779823535 @default.
• W2183863241 hasConcept C2780775027 @default.
• W2183863241 hasConcept C2781121885 @default.
• W2183863241 hasConcept C2911091166 @default.
• W2183863241 hasConcept C54355233 @default.
• W2183863241 hasConcept C71924100 @default.
• W2183863241 hasConcept C81885089 @default.
• W2183863241 hasConcept C86803240 @default.
• W2183863241 hasConcept C90924648 @default.
• W2183863241 hasConceptScore W2183863241C126322002 @default.
• W2183863241 hasConceptScore W2183863241C143998085 @default.
• W2183863241 hasConceptScore W2183863241C203014093 @default.
• W2183863241 hasConceptScore W2183863241C2776601000 @default.
• W2183863241 hasConceptScore W2183863241C2776694085 @default.
• W2183863241 hasConceptScore W2183863241C2778461978 @default.
• W2183863241 hasConceptScore W2183863241C2779050716 @default.
• W2183863241 hasConceptScore W2183863241C2779823535 @default.
• W2183863241 hasConceptScore W2183863241C2780775027 @default.
• W2183863241 hasConceptScore W2183863241C2781121885 @default.
• W2183863241 hasConceptScore W2183863241C2911091166 @default.
• W2183863241 hasConceptScore W2183863241C54355233 @default.
• W2183863241 hasConceptScore W2183863241C71924100 @default.
• W2183863241 hasConceptScore W2183863241C81885089 @default.
• W2183863241 hasConceptScore W2183863241C86803240 @default.
• W2183863241 hasConceptScore W2183863241C90924648 @default.
• W2183863241 hasIssue "1" @default.
• W2183863241 hasLocation W21838632411 @default.
• W2183863241 hasOpenAccess W2183863241 @default.
• W2183863241 hasPrimaryLocation W21838632411 @default.
• W2183863241 hasRelatedWork W1158218703 @default.
• W2183863241 hasRelatedWork W16896924 @default.
• W2183863241 hasRelatedWork W1923906154 @default.
• W2183863241 hasRelatedWork W2033096478 @default.
• W2183863241 hasRelatedWork W2128143973 @default.
• W2183863241 hasRelatedWork W2178253779 @default.
• W2183863241 hasRelatedWork W2183863241 @default.
• W2183863241 hasRelatedWork W2516086162 @default.
• W2183863241 hasRelatedWork W2998600066 @default.
• W2183863241 hasRelatedWork W2948058885 @default.

• next